<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077567</url>
  </required_header>
  <id_info>
    <org_study_id>TS152-3002-JA</org_study_id>
    <nct_id>NCT04077567</nct_id>
  </id_info>
  <brief_title>An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and efficacy of TS-152 in subjects with Rheumatoid Arthritis
      who have completed the previous study (TS152-3000-JA study or TS152-3001-JA study).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>To evaluate the Long-term safety of TS-152 in RA patients by incidence of adverse events which include vital signs, and clinical laboratory parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>Percentage of Subjects who meet the American College of Rheumatology 20% (ACR20) Criteria from baseline of previous study (TS152-3001-JA or TS152-3001-JA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">505</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>TS-152 30mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS-152 30mg subcutaneously (SC) every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-152 80mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS-152 80mg subcutaneously (SC) every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-152</intervention_name>
    <description>30mg,80mg</description>
    <arm_group_label>TS-152 30mg SC</arm_group_label>
    <arm_group_label>TS-152 80mg SC</arm_group_label>
    <other_name>ozoralizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At visit1(-4 weeks), Subject must be fully informed about the study and must obtain
             written informed consent from the subject himself.

          2. At Visit2(0 week), Subjects must have completed the previous study (TS152-3000-JA or
             TS152-3001-JA) ,and must have completed all evaluations required at the follow-up
             visit.

        etc.

        Exclusion Criteria:

          1. Subjects who had serious adverse drug reactions in the previous study.

          2. At Visit1(-4 weeks) or Visit2 (0 week), Subjects who have not recovered from
             clinically important adverse events.

        etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Taisho Pharmaceutical Co., Ltd.</last_name>
    <phone>81-3-3985-1413</phone>
    <email>clinical-trials_CTG@taisho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

